Laboratory testing of anti-drug antibodies in biological therapy of inflammatory bowel disease
Kovács Krisztián
Theoretical and Translational Medicine Division
Dr. Kellermayer Miklós
Semmelweis Egyetem Gyermekgyógyászati Klinika tanterem, Bókay u.
2026-06-19 14:00:00
Clinical application of basic science results
Dr. Vásárhelyi Barna
Dr. Cseh Áron
Dr. Patai Árpád
Dr. Shemirani Amir-Houshang
Dr. Domján Gyula Géza
Dr. Szabó Dolóresz Ildikó
Dr. Szalay Balázs
Overall, the novelty of our findings is as follows:
1. In a real-world pediatric and adult IBD patient population, we demonstrated that a combination of routinely available clinical variables can predict antibody formation associated with biologic therapies to a moderate but clinically relevant extent.
2. Using a hierarchical logistic regression model, we demonstrated that infliximab treatment is an independent, significant risk factor for the development of immunogenicity, and that the duration of treatment further increases this risk.
3. We were the first to identify that three-way interactions between age at disease onset, IBD subtype, and type of therapy significantly modify the risk of immunogenicity.
4. We confirmed that the probability of antibody formation is significantly higher in childhood-onset ulcerative colitis treated with infliximab.
5. We demonstrated that prolonged exposure to infliximab further increases the risk of immunogenicity in ulcerative colitis.
6. In patients receiving second- and third-line biological therapies, antibody formation was determined predominantly by the immunogenicity of the administered biologic rather than by patient-related characteristics, including age, disease type, or prior biologic exposure. This finding supports the use of biologic-specific TDM to guide therapy optimization.
